Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Metrics to compare | CONB | Peers Peers - average of corresponding metrics from companies closely matching CONB: LUPIN, COHANCE, SUNPHARMA, LAURUSLABS, GLENMARK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCONBPeersSector |
---|---|---|---|---|
P/E Ratio | 49.4x | 31.3x | −0.5x | |
PEG Ratio | 3.62 | 0.22 | 0.00 | |
Price/Book | 9.7x | 3.7x | 2.6x | |
Price / LTM Sales | 14.8x | 3.6x | 3.3x | |
Upside (Analyst Target) | 11.8% | 10.0% | 38.9% | |
Fair Value Upside | Unlock | 9.6% | 5.4% | Unlock |